Web site is worth a read
https://neuroscientific.com/our-science/
Biopharmaceutical innovation and world class R&DNSB (ASX:NSB) is a drug development company focused on developing peptide-based pharmaceutical drugs for the treatment of neurodegenerative conditions with high unmet medical need.The NSB product portfolio includes several therapeutic peptides that are modeled on the domains of a naturally occurring protein called Metallothionein-II (MT-II).EmtinB is the lead candidate that has shown to closely mimic the neuroprotective and neuroregenerative ability of MT-II.
EmtinB is currently being developed as a treatment for neurodegenerative dementia and Alzheimer’s disease, and degenerative conditions of the optic nerve.
- Forums
- ASX - By Stock
- NSB
- Ann: Quarterly Activities/Appendix 4C Cash Flow Report
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-21
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
4.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $5.784M |
Open | High | Low | Value | Volume |
4.0¢ | 4.0¢ | 4.0¢ | $10K | 250K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 200000 | 3.7¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
4.5¢ | 50000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 200000 | 0.037 |
2 | 400000 | 0.035 |
2 | 329000 | 0.034 |
2 | 133332 | 0.030 |
1 | 71036 | 0.028 |
Price($) | Vol. | No. |
---|---|---|
0.045 | 50000 | 1 |
0.050 | 229084 | 3 |
0.051 | 75976 | 1 |
0.053 | 926682 | 2 |
0.055 | 249999 | 2 |
Last trade - 15.11pm 17/06/2024 (20 minute delay) ? |
Featured News
NSB (ASX) Chart |
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non Executive Director
Simon Kidston
Non Executive Director
SPONSORED BY The Market Online